Your browser doesn't support javascript.
loading
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara, Kohei; Iwata, Hiroji; Takahashi, Shunji; Tamura, Kenji; Park, Haeseong; Modi, Shanu; Tsurutani, Junji; Kadowaki, Shigenori; Yamaguchi, Kensei; Iwasa, Satoru; Saito, Kaku; Fujisaki, Yoshihiko; Sugihara, Masahiro; Shahidi, Javad; Doi, Toshihiko.
Afiliación
  • Shitara K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: kshitara@east.ncc.go.jp.
  • Iwata H; Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
  • Takahashi S; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Tamura K; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Park H; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Modi S; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tsurutani J; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan; Department of Medical Oncology, Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
  • Kadowaki S; Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
  • Yamaguchi K; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Iwasa S; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Saito K; Research and Development, Daiichi Sankyo Co, Ltd, Tokyo, Japan.
  • Fujisaki Y; Research and Development, Daiichi Sankyo Co, Ltd, Tokyo, Japan.
  • Sugihara M; Biostatistics and Data Management, Daiichi Sankyo Co, Ltd, Tokyo, Japan.
  • Shahidi J; Research and Development, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.
  • Doi T; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Lancet Oncol ; 20(6): 827-836, 2019 06.
Article en En | MEDLINE | ID: mdl-31047804
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Camptotecina / Terapia Recuperativa / Receptor ErbB-2 / Inmunoconjugados / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Camptotecina / Terapia Recuperativa / Receptor ErbB-2 / Inmunoconjugados / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido